Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorWei Hu
About this trial
The goal of this clinical trial is to learn if semaglutide works to treat acute ischemic stroke (AIS). It will also learn about the safety of semaglutide in AIS. The main question it aims to answer is: Does semaglutide improve the 90-days functional outcome in participants with acute large vessel occlusion who receive the endovascular treatment (EVT)? Researchers will compare semaglutide injection to non-injection to see if semaglutide works to improve the functional outcome in participants with EVT.
Participants will:
* Receive 0.5mg semaglutide injection before (Day 0) and 1 week (Day 7) after EVT , or EVT alone. * Have additional blood test before and after EVT. * Receive neurological assessment before EVT, Day 1, Day 3, Day 5-7 after EVT or on hospital discharge (whichever earlier), Day 90±14 after EVT. Audio or video of the assessment may be recorded if possible. * Receive brain CT + CT angiogram + CT perfusion and MRI after EVT, where the CT scan may be repetitive.
Eligibility criteria
Qualifiers
LVO stroke at terminal ICA, M1 or dominant M2 with an LKW-to-randomization ≤24 hours
Age ≥ 18 years old
National Institute of Health Stroke Scale ≥ 6 at the time of brain imaging
Acute LVO stroke due to thromboembolism or intracranial stenosis
Disqualifiers
Use of intravenous thrombolytic therapy (alteplase or tenecteplase)
Pre-stroke mRS > 2 for patients <80 years and > 1 for patients ≥ 80 years old
Intracranial hemorrhage or brain tumour on initial imaging (except small meningiomas)
Simultaneous occlusion of bilateral anterior circulation, or both anterior and posterior circulation
Trial design
Treatments tested in this trial
- Semaglutide 0.5 mg
- Standard medical treatment
Treatment groups
390 Participants
are divided into 2 treatment groupsSponsors and collaborators
Wei Hu
Lead sponsor
The First Affiliated Hospital of University of Science and Technology of China
Sponsor institution
Chinese University of Hong Kong
Collaborator
Source ClinicalTrials.gov